In the context of colon cancer, targeting and degrading Wilms’ tumor 1-associating protein (WTAP) with carbonic anhydrase IV successfully restored free WT1 proteins capable of inhibiting the Wnt/β-catenin pathway, demonstrating the potential benefits of WTAP-targeting therapies (88). This evidence concerns the gene WTAP and malignant colon neoplasm.